RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 66 filers reported holding RA PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $4,803,000 | -83.5% | 100,043 | -83.9% | 0.01% | -69.4% |
| Q4 2019 | $29,151,000 | +831.9% | 621,166 | +369.6% | 0.04% | +620.0% |
| Q3 2019 | $3,128,000 | -21.2% | 132,278 | +0.2% | 0.01% | -16.7% |
| Q2 2019 | $3,971,000 | -56.3% | 132,065 | -67.5% | 0.01% | -57.1% |
| Q1 2019 | $9,093,000 | +21.2% | 405,940 | -1.5% | 0.01% | +16.7% |
| Q4 2018 | $7,500,000 | +410.2% | 412,066 | +407.0% | 0.01% | +500.0% |
| Q3 2018 | $1,470,000 | -40.7% | 81,278 | -67.4% | 0.00% | -33.3% |
| Q2 2018 | $2,480,000 | -30.4% | 249,287 | -62.9% | 0.00% | -40.0% |
| Q1 2018 | $3,564,000 | -5.7% | 671,262 | +50.9% | 0.01% | 0.0% |
| Q4 2017 | $3,780,000 | -59.0% | 444,697 | -29.6% | 0.01% | -64.3% |
| Q3 2017 | $9,224,000 | +149.0% | 631,757 | +219.5% | 0.01% | +100.0% |
| Q2 2017 | $3,705,000 | +278.4% | 197,715 | +330.0% | 0.01% | +250.0% |
| Q1 2017 | $979,000 | +4.1% | 45,978 | -25.7% | 0.00% | 0.0% |
| Q4 2016 | $940,000 | – | 61,888 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 6,138,797 | $294,724,000 | 15.40% |
| RA Capital Management | 4,858,260 | $233,245,000 | 7.37% |
| HAVENS ADVISORS LLC | 143,266 | $6,878,000 | 6.70% |
| BARDIN HILL MANAGEMENT PARTNERS LP | 609,614 | $29,267,000 | 6.40% |
| OMNI PARTNERS LLP | 1,052,744 | $50,542,000 | 4.45% |
| HBK INVESTMENTS L P | 2,004,042 | $96,214,000 | 4.03% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,005,600 | $96,289,000 | 3.83% |
| Versor Investments LP | 1,108,845 | $53,236,000 | 3.53% |
| OXFORD ASSET MANAGEMENT LLP | 461,016 | $22,133,000 | 3.12% |
| HighVista Strategies LLC | 63,222 | $3,035,000 | 2.81% |